Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

The signaling adaptor BCAP inhibits NLRP3 and NLRC4 inflammasome activation in macrophages through interactions with Flightless-1.

Carpentier SJ, Ni M, Duggan JM, James RG, Cookson BT, Hamerman JA.

Sci Signal. 2019 May 14;12(581). pii: eaau0615. doi: 10.1126/scisignal.aau0615.

PMID:
31088976
2.

Cutting Edge: BCAP Promotes Lupus-like Disease and TLR-Mediated Type I IFN Induction in Plasmacytoid Dendritic Cells.

Chu T, Ni M, Chen C, Akilesh S, Hamerman JA.

J Immunol. 2019 May 1;202(9):2529-2534. doi: 10.4049/jimmunol.1801267. Epub 2019 Apr 1.

PMID:
30936294
3.

Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes.

Akilesh HM, Buechler MB, Duggan JM, Hahn WO, Matta B, Sun X, Gessay G, Whalen E, Mason M, Presnell SR, Elkon KB, Lacy-Hulbert A, Barnes BJ, Pepper M, Hamerman JA.

Science. 2019 Jan 11;363(6423). pii: eaao5213. doi: 10.1126/science.aao5213.

PMID:
30630901
4.

B cell adaptor for PI3-kinase (BCAP) modulates CD8+ effector and memory T cell differentiation.

Singh MD, Ni M, Sullivan JM, Hamerman JA, Campbell DJ.

J Exp Med. 2018 Sep 3;215(9):2429-2443. doi: 10.1084/jem.20171820. Epub 2018 Aug 9.

5.

A Novel Strategy to Prevent Advanced Atherosclerosis and Lower Blood Glucose in a Mouse Model of Metabolic Syndrome.

Kanter JE, Kramer F, Barnhart S, Duggan JM, Shimizu-Albergine M, Kothari V, Chait A, Bouman SD, Hamerman JA, Hansen BF, Olsen GS, Bornfeldt KE.

Diabetes. 2018 May;67(5):946-959. doi: 10.2337/db17-0744. Epub 2018 Feb 26.

6.

cGAS-mediated control of blood-stage malaria promotes Plasmodium-specific germinal center responses.

Hahn WO, Butler NS, Lindner SE, Akilesh HM, Sather DN, Kappe SH, Hamerman JA, Gale M Jr, Liles WC, Pepper M.

JCI Insight. 2018 Jan 25;3(2). pii: 94142. doi: 10.1172/jci.insight.94142. eCollection 2018 Jan 25.

7.

BCAP inhibits proliferation and differentiation of myeloid progenitors in the steady state and during demand situations.

Duggan JM, Buechler MB, Olson RM, Hohl TM, Hamerman JA.

Blood. 2017 Mar 16;129(11):1503-1513. doi: 10.1182/blood-2016-06-719823. Epub 2017 Jan 13.

8.

Cutting Edge: Direct Sensing of TLR7 Ligands and Type I IFN by the Common Myeloid Progenitor Promotes mTOR/PI3K-Dependent Emergency Myelopoiesis.

Buechler MB, Akilesh HM, Hamerman JA.

J Immunol. 2016 Oct 1;197(7):2577-82. doi: 10.4049/jimmunol.1600813. Epub 2016 Aug 26.

9.

Negative regulation of TLR signaling in myeloid cells--implications for autoimmune diseases.

Hamerman JA, Pottle J, Ni M, He Y, Zhang ZY, Buckner JH.

Immunol Rev. 2016 Jan;269(1):212-27. doi: 10.1111/imr.12381. Review.

10.

Hematopoietic and nonhematopoietic cells promote Type I interferon- and TLR7-dependent monocytosis during low-dose LCMV infection.

Buechler MB, Gessay GM, Srivastava S, Campbell DJ, Hamerman JA.

Eur J Immunol. 2015 Nov;45(11):3064-72. doi: 10.1002/eji.201445331. Epub 2015 Sep 14.

11.

The Tec Kinase-Regulated Phosphoproteome Reveals a Mechanism for the Regulation of Inhibitory Signals in Murine Macrophages.

Tampella G, Kerns HM, Niu D, Singh S, Khim S, Bosch KA, Garrett ME, Moguche A, Evans E, Browning B, Jahan TA, Nacht M, Wolf-Yadlin A, Plebani A, Hamerman JA, Rawlings DJ, James RG.

J Immunol. 2015 Jul 1;195(1):246-56. doi: 10.4049/jimmunol.1403238. Epub 2015 May 29.

12.

Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells.

Giltiay NV, Chappell CP, Sun X, Kolhatkar N, Teal TH, Wiedeman AE, Kim J, Tanaka L, Buechler MB, Hamerman JA, Imanishi-Kari T, Clark EA, Elkon KB.

J Exp Med. 2013 Nov 18;210(12):2773-89. doi: 10.1084/jem.20122798. Epub 2013 Oct 21.

13.

TLR-2/TLR-4 TREM-1 signaling pathway is dispensable in inflammatory myeloid cells during sterile kidney injury.

Campanholle G, Mittelsteadt K, Nakagawa S, Kobayashi A, Lin SL, Gharib SA, Heinecke JW, Hamerman JA, Altemeier WA, Duffield JS.

PLoS One. 2013 Jul 3;8(7):e68640. doi: 10.1371/journal.pone.0068640. Print 2013.

14.

Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice.

Sun X, Wiedeman A, Agrawal N, Teal TH, Tanaka L, Hudkins KL, Alpers CE, Bolland S, Buechler MB, Hamerman JA, Ledbetter JA, Liggitt D, Elkon KB.

J Immunol. 2013 Mar 15;190(6):2536-43. doi: 10.4049/jimmunol.1202689. Epub 2013 Feb 4.

15.

β(2) integrins inhibit TLR responses by regulating NF-κB pathway and p38 MAPK activation.

Yee NK, Hamerman JA.

Eur J Immunol. 2013 Mar;43(3):779-92. doi: 10.1002/eji.201242550. Epub 2013 Feb 11.

16.

Cutting edge: Type I IFN drives emergency myelopoiesis and peripheral myeloid expansion during chronic TLR7 signaling.

Buechler MB, Teal TH, Elkon KB, Hamerman JA.

J Immunol. 2013 Feb 1;190(3):886-91. doi: 10.4049/jimmunol.1202739. Epub 2013 Jan 9.

17.

Tracing conidial fate and measuring host cell antifungal activity using a reporter of microbial viability in the lung.

Jhingran A, Mar KB, Kumasaka DK, Knoblaugh SE, Ngo LY, Segal BH, Iwakura Y, Lowell CA, Hamerman JA, Lin X, Hohl TM.

Cell Rep. 2012 Dec 27;2(6):1762-73. doi: 10.1016/j.celrep.2012.10.026. Epub 2012 Nov 29.

18.

B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K.

Ni M, MacFarlane AW 4th, Toft M, Lowell CA, Campbell KS, Hamerman JA.

Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):267-72. doi: 10.1073/pnas.1111957108. Epub 2011 Dec 20.

19.

TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells.

Ito H, Hamerman JA.

Eur J Immunol. 2012 Jan;42(1):176-85. doi: 10.1002/eji.201141679. Epub 2011 Dec 12.

20.

S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation.

Averill MM, Barnhart S, Becker L, Li X, Heinecke JW, Leboeuf RC, Hamerman JA, Sorg C, Kerkhoff C, Bornfeldt KE.

Circulation. 2011 Mar 22;123(11):1216-26. doi: 10.1161/CIRCULATIONAHA.110.985523. Epub 2011 Mar 7.

21.

Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes.

Sanda S, Bollyky J, Standifer N, Nepom G, Hamerman JA, Greenbaum C.

Clin Immunol. 2010 Aug;136(2):170-3. doi: 10.1016/j.clim.2010.04.009. Epub 2010 May 18.

PMID:
20483667
22.

DAP12 is required for macrophage recruitment to the lung in response to cigarette smoke and chemotaxis toward CCL2.

Koth LL, Cambier CJ, Ellwanger A, Solon M, Hou L, Lanier LL, Abram CL, Hamerman JA, Woodruff PG.

J Immunol. 2010 Jun 1;184(11):6522-8. doi: 10.4049/jimmunol.0901171. Epub 2010 Apr 26.

23.

The expanding roles of ITAM adapters FcRgamma and DAP12 in myeloid cells.

Hamerman JA, Ni M, Killebrew JR, Chu CL, Lowell CA.

Immunol Rev. 2009 Nov;232(1):42-58. doi: 10.1111/j.1600-065X.2009.00841.x. Review.

24.

TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria.

N'Diaye EN, Branda CS, Branda SS, Nevarez L, Colonna M, Lowell C, Hamerman JA, Seaman WE.

J Cell Biol. 2009 Jan 26;184(2):215-23. doi: 10.1083/jcb.200808080.

25.

Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.

Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ.

Cancer Res. 2008 Apr 15;68(8):2972-83. doi: 10.1158/0008-5472.CAN-08-0045.

26.

Increased TLR responses in dendritic cells lacking the ITAM-containing adapters DAP12 and FcRgamma.

Chu CL, Yu YL, Shen KY, Lowell CA, Lanier LL, Hamerman JA.

Eur J Immunol. 2008 Jan;38(1):166-73.

27.

The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection.

Kim J, Chang CK, Hayden T, Liu FC, Benjamin J, Hamerman JA, Lanier LL, Kang SM.

J Immunol. 2007 Nov 15;179(10):6416-20.

28.

Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12.

Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL.

J Immunol. 2006 Aug 15;177(4):2051-5.

29.

Inhibition of immune responses by ITAM-bearing receptors.

Hamerman JA, Lanier LL.

Sci STKE. 2006 Jan 31;2006(320):re1. Review.

PMID:
16449667
30.

Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12.

Hamerman JA, Tchao NK, Lowell CA, Lanier LL.

Nat Immunol. 2005 Jun;6(6):579-86. Epub 2005 May 15. Erratum in: Nat Immunol. 2009 Feb;10(2):223. Dosage error in article text.

31.

Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells.

Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL.

J Immunol. 2005 Feb 15;174(4):1922-31.

32.

NK cells in innate immunity.

Hamerman JA, Ogasawara K, Lanier LL.

Curr Opin Immunol. 2005 Feb;17(1):29-35. Review.

PMID:
15653307
33.

A Structural basis for the association of DAP12 with mouse, but not human, NKG2D.

Rosen DB, Araki M, Hamerman JA, Chen T, Yamamura T, Lanier LL.

J Immunol. 2004 Aug 15;173(4):2470-8.

34.

NKG2D blockade prevents autoimmune diabetes in NOD mice.

Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, Lanier LL.

Immunity. 2004 Jun;20(6):757-67.

35.

Cutting edge: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor.

Hamerman JA, Ogasawara K, Lanier LL.

J Immunol. 2004 Feb 15;172(4):2001-5.

36.

NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules.

Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES, Lanier LL.

J Exp Med. 2003 May 19;197(10):1245-53.

37.

NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases.

Zompi S, Hamerman JA, Ogasawara K, Schweighoffer E, Tybulewicz VL, Di Santo JP, Lanier LL, Colucci F.

Nat Immunol. 2003 Jun;4(6):565-72. Epub 2003 May 11.

38.

Impairment of NK cell function by NKG2D modulation in NOD mice.

Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL.

Immunity. 2003 Jan;18(1):41-51.

39.

Cutting edge: the minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D.

Cerwenka A, O'Callaghan CA, Hamerman JA, Yadav R, Ajayi W, Roopenian DC, Joyce S, Lanier LL.

J Immunol. 2002 Apr 1;168(7):3131-4.

40.

Serpin 2a is induced in activated macrophages and conjugates to a ubiquitin homolog.

Hamerman JA, Hayashi F, Schroeder LA, Gygi SP, Haas AL, Hampson L, Coughlin P, Aebersold R, Aderem A.

J Immunol. 2002 Mar 1;168(5):2415-23.

41.
42.

Isolation and characterization of monoclonal antibodies directed against novel components of macrophage phagosomes.

Morrissette NS, Gold ES, Guo J, Hamerman JA, Ozinsky A, Bedian V, Aderem AA.

J Cell Sci. 1999 Dec;112 ( Pt 24):4705-13.

43.

Differential effects of manipulating signaling in early T cell development in intestinal intraepithelial lymphocytes and thymocytes.

Page ST, Bogatzki LY, Hamerman JA, Malissen M, Perlmutter RM, Pullen AM.

Int Immunol. 1999 Feb;11(2):169-77.

PMID:
10069415
44.

Intestinal intraepithelial lymphocytes include precursors committed to the T cell receptor alpha beta lineage.

Page ST, Bogatzki LY, Hamerman JA, Sweenie CH, Hogarth PJ, Malissen M, Perlmutter RM, Pullen AM.

Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9459-64.

45.

Distinct methylation states of the CD8 beta gene in peripheral T cells and intraepithelial lymphocytes.

Hamerman JA, Page ST, Pullen AM.

J Immunol. 1997 Aug 1;159(3):1240-6.

PMID:
9233619

Supplemental Content

Loading ...
Support Center